Venus Medtech (Hangzhou) (HKG:2500) completed the enrollment of all 150 patients for a confirmatory clinical study of Cardiovalve in Europe, a Friday Hong Kong bourse filing said.
Cardiovalve is the medical device maker's transcatheter valve replacement system.